WATCH VIDEO & READ: DCI Partners with OncLive for Breast Cancer Webinar
UPDATE (DECEMBER 2):
The virtual meeting covered escalation and de-escalation strategies in early-stage HER2-positive breast cancer, the emergence of fam-trastuzumab deruxtecan-nxki (Enhertu) in metastatic HER2-positive breast cancer, the role of CDK4/6 inhibitors in hormone receptor (HR)–positive, HER2-negative breast cancer, and recent advances that have expanded options for patients with triple-negative breast cancer (TNBC).
READ: Progress Made Across Breast Cancer Paradigm Sets the Stage for Improved Sequencing and Future Research featuring Sarah Sammons, MD, Gretchen Kimmick, MD, MS, Kelly Westbrook, MD, Susan Dent, MD, and Carey Anders, MD.
WATCH & READ: Dr. Kimmick on the Evolving HER2+ Breast Cancer Treatment Paradigm
WATCH & READ: Dr. Sammons on the Clinical Implications of DESTINY-Breast03 in HER2+ Breast Cancer
UPDATE (SEPT. 27): This event, previously advertised as an in-person event in Durham, will now be presented in webinar form. Note also the time change below.
OncLive, in collaboration with the Duke Cancer Institute Breast Cancer Disease Group, will host a webinar — "Institutional Perspectives in Cancer: Breast Cancer" — on Tuesday, October 26, from 6:30 p.m. to 8 p.m.
Chaired by Sarah Sammons, MD, the event will include practice changing updates presented by DCI faculty Gretchen Kimmick, MD, MS; Kelly Westbrook, MD; Carey Anders, MD; and Susan Dent, MD.
- Early Stage HER2+ Breast Cancer
- Metastatic HER2+ Breast Cancer
- Immunotherapeutic Advances in Triple-Negative Breast Cancer
- Life prolonging therapies in Advanced HR+/HER2-
The program will also include a LIVE Q & A session with the presenters.
This educational event is one in a series of OncLive Institutional Perspectives in Cancer events — the virtual version of OncLive's in-person State of the Science Summit meetings. Academic and community-based physicians and health care professionals are the target audience. Expert faculty educate health care professionals on the clinical benefits associated with the new science driving new thinking in cancer management and event attendees improve their knowledge of novel treatment approaches.
View Program Agenda